key: cord-0760249-opv2paeq
authors: Güler, Günnur; Özdemir, Helin; Omar, Dilara; Akdoğan, Gül
title: Coronavirus disease 2019 (COVID-19): Biophysical and biochemical aspects of SARS-CoV-2 and general characteristics
date: 2021-05-24
journal: Prog Biophys Mol Biol
DOI: 10.1016/j.pbiomolbio.2021.05.007
sha: e693326c95ecf79d4e54ad07f9e3d078717a2137
doc_id: 760249
cord_uid: opv2paeq

The coronavirus disease (COVID-19) arises from the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) which is an enveloped RNA virus. COVID-19 has rapidly spread throughout the world by infecting more than 143 million people and causing 3.04 million deaths worldwide by 22 April 2021, confirmed by the World Health Organization. It caused great concern and pandemic all over the world, therewithal there has not been found any specific and efficient treatment yet. In the current review, we aimed to define the biophysical and biochemical aspects of SARS-CoV-2, including renin-angiotensin-system, cytokine storms, receptor binding, protein structural and functional features, molecular interactions, and conformational changes that take place during viral attachment and entering into human cells. It was also aimed to highlight the general hallmarks of COVID-19, including treatment strategies, diagnosis and even prevention. Thus, this review will serve as an updated comprehensive body of information and discussion on COVID-19 and will help the molecular scientists, biophysicists, clinicians, as well as medical engineers. Thereby, further understanding of COVID-19 will provide novel insights and advances in development of therapeutic potentials and vaccine alternatives as well as in detection of specific targets for diagnosis.

The smallest structural protein of SARS-CoV-2 is the E protein which is an integral membrane protein found in the viral membrane. It plays a number of key roles in the viral replication such as envelope formation, viral assembly, and it functions as ion channels and interacts with host cell proteins Naqvi et al., 2020; Yoshimoto, 2020) . The most abundant structural protein is the M protein which is an integral membrane protein that spans the viral membrane. It interacts with other main viral proteins and has significant role in the RNA packaging and viral assembly, shaping the viral envelope (Naqvi et al., 2020; Tang et al., 2020; Yoshimoto, 2020) . The N protein is a ~54 kDa protein that binds to viral RNA structurally and assembles into a helical ribonucleocapsid. A recent publication reported that its N-terminal is the RNA-binding domain while its C-terminal domain is responsible for homodimerization (PDB ID: 6WZO), very similar to that of SARS-CoV and MERS-CoV, and it forms large oligomers (tetramers) likely through nucleic acid-protein and protein-protein interactions . This nucleocapsid phosphoprotein is involved in the transcription, replication and packaging of the viral RNA (Naqvi et al., 2020; Schoeman and Fielding, 2019; Ye et al., 2020; Yoshimoto, 2020) . The spike (S) proteins coated with polysaccharides are glycoproteins that a large number of S proteins protrude like a pedal-shaped spike on the surface of the virus envelope J o u r n a l P r e -p r o o f ( Fig. 2A) . The S protein has 2 vital subunits for binding (S1 subunit) and fusion (S2 subunit) with the host cell. Briefly, the S protein facilities the entry into the human cells by attaching to a specific receptor (ACE2) located on the surface of the host cell (Fig. 2B ). Those main structural proteins addressed above have collateral effects on the viral infection, and thus, they can be considered as potential drug targets as well. In the following sections of biophysical parts, the characteristics of spike protein can be comprehended in a more detailed way, which can help with the understanding of the connection of the virus with the human cells. 

Currently, it is well known that the COVID-19 infection initiates with the interaction of SARS-CoV-2 spike (S) protein (termed SARS-CoV-2 S) with human cells as a first step (Fig. 2B) . The S proteins of both SARS-CoV-2 and SARS-CoV bind to human ACE2 receptor at high affinities in the nanomolar range to enter and invade the target human cells (Walls et al., 2020; . Thus, SARS-CoV-2 S protein is an essential target for therapeutic, diagnostic and biological research.

J o u r n a l P r e -p r o o f SARS-CoV-2 S protein has a high amino acid sequence identity with the S glycoproteins of SARS-CoV (76%) and BatCoV-RaTG13 (97%) (Walls et al., 2020; Yoshimoto, 2020; Zhou et al., 2020) . SARS-CoV-2 has a longer spike protein with a length of 1273 amino acids in comparison to both SARS-CoV and MERS-CoV . A recent cryo-EM structural data revealed that SARS-CoV-2 S protein has a total structural weight of ~438 kDa (Pdb ID: 6VXX) (Walls et al., 2020) . The S protein, a heavilyglycosylated type I transmembrane protein, mediates attachment and entry into target cells. This large homotrimeric S protein, decorated with 22 N-linked glycans per protomer (Walls et al., 2020; Watanabe et al., 2020) , is known for making protrusions like a crown on the viral surface. The S protein comprises of three parts: (i) an ectodomain having a triangular cross-section with a length of 160Å (ii) a single-pass transmembrane anchor, and (iii) an intracellular tail (Li, 2016; Walls et al., 2020) ( Fig. 2A) . The ectodomain segment of homotrimeric S protein has S1 and S2 functional subunits in each monomer, which are associated with the receptor recognition and membrane fusion, respectively ( Fig. 3A and 3B) . Accordingly, the S1 subunit exhibiting a V-shaped structure comprises a receptor binding domain (RBD) that binds to the receptor protein ACE2 located on the host cell surface, providing viral attachment. This is followed by the host cell membrane fusion through the S2 subunit so that the viral genomes can enter into target cells (Cascella et al., 2020; Li, 2016; Mathewson et al., 2008; Paul S. and Stanley, 2007; Walls et al., 2020) . The S2 subunit harbours mainly α-helical secondary structures (Fig. 3B ). It contains a fusion peptide (FP) region, heptad repeats (HR1 and HR2), a solely 40% identity with other SARS-CoVs (Cascella et al., 2020; Walls et al., 2020) . Thus, the S2 subunit and the conserved motif in the S1 subunit can be thought as potential targets for neutralizing transmembrane domain (TM) and cytoplasmic domain, which is conserved in SARS-CoV-2 sharing 88% sequence identity, whereas the amino acid sequence of the receptorbinding domain in S1 shows antibodies against COVID-19.

Recent cryo-EM data (Carrique et al., 2020; Toelzer et al., 2020) have revealed bound unsaturated fatty acids on the RBD of the trimeric S protein. It was reported that the RBDs of trimeric SARS-CoV-2 S protein tightly and specifically binds to the essential free fatty acid linoleic acid in three composite J o u r n a l P r e -p r o o f binding pockets (Toelzer et al., 2020) . Again recently reported, the acyl chains of unsaturated fatty acids bind to a hydrophobic pocket in one RBD of the trimeric S protein while the polar headgroups attach to an adjacent RBD, showing that lipid-like molecules modulate the S protein stability.

Thereby, it was proposed in both studies that these binding pockets could be a promising target for development of small molecule-inhibitors or other therapeutics against SARS- CoV-2 (Carrique et al., 2020; Toelzer et al., 2020) . 

A cascade of events occurring during receptor attachment and proteolytic processing of trimeric S protein is required for cellular entry of SARS-CoV-2. The S protein is cleaved into S1 and S2 subunits by proteases on the host cell membrane. Significantly, a furin cleavage site was determined at the boundary between the S1/S2 subunits of the SARS-CoV-2 S protein, cleaved during S biogenesis (Walls et al., 2020) . This S1/S2 junction is located in a disordered, solvent-exposed loop structure of the S protein (Fig.3B ). This polybasic furin cleavage site (amino acid sequence: QTQTNSPRRARSVASQSIIA) is absent in the S protein of SARS-CoV (Yoshimoto, 2020) . Additionally, the S2 subunit involves a protease cleavage site (called S2' site) at the upstream of the hydrophobic fusion peptide. The S 2 ' cleavage site of SARS-CoV-2 S protein was found similar to that of SARS-CoV (Hoffmann et al., 2020) . Recently determined that the S protein is cleaved at the S1/S2 and S 2 ' sites by host cell proteases such as furin and TMPRSS2 to activate the spike protein for a tight binding to the ACE2 receptor and for membrane fusion through multiple conformational alterations. This is crucial for expanding of SARS-CoV-2 cell and modulation of tropism, transmissibility and pathogenicity (Hoffmann et al., 2020; Walls et al., 2020) . It was also explicitly showed that SARS-CoV-2 requires both host cell ACE2 receptor and serine protease TMPRSS2 for S protein priming to enter into the host cell, and thus, it was suggested that SARS-CoV-2 can be blocked by using TMPRSS2 inhibitors against COVID-19 (Hoffmann et al., 2020) .

The trimeric S protein exhibits concerted conformational changes crucial for receptor binding and membrane fusion. Recently, open and closed conformations of SARS-CoV-2 spike glycoprotein has been detected (Walls et al., 2020) . Accordingly, in the closed state of S trimers, the recognition motifs (RBMs) in the RBD of the S1 subunit are buried at the interface between protomers (Fig. 3A ).

However, in the open conformation of S1 at the trimer apex, the RBMs are exposed (Fig. 3B ) which is required for ACE2 interaction followed by S2 conformational alterations in a concerted manner for protease cleavage at the S 2 ' site, membrane fusion and entry into target cells. Hence, Walls et al.

(2020) proposed that trimeric S proteins of highly pathogenic human coronaviruses should undergo partially opened states, but human coronaviruses with common colds should have largely closed trimeric S proteins (Walls et al., 2020) . In line with this study, the receptor-accessible (open or up conformation) and receptor-inaccessible (closed or down conformation) states of S trimers have been structurally determined (Fig. 3C ). In the prefusion conformation of S J o u r n a l P r e -p r o o f trimer, a single receptor-binding domain (RBD) of S1 in one protomer rotates up (receptor-accessible state) and becomes exposed to receptor binding (Fig. 3A) . This renders the S trimer less stable, and results in a highly stable postfusion conformation of the S2 subunit and membrane fusion. In the closed or down conformation, RBD of S1 is angled through the central trimeric cavity . Recently, a stabilized prefusion SARS-CoV-2 spike ectodomain has been designed to enhance the yield and stability so that it can be a promising candidate for vaccine and diagnostic developments . Additionally, enhanced yields of high quality SARS-CoV-2 S proteins (recombinant S proteins) that have appropriate biochemical and biophysical properties were generated for investigations in both clinical and basic science (Herrera et al., 2020) .

SARS-CoV-2 S protein binds to human cell receptor ACE2 with a high affinity of 14.7 nM analyzed by using surface plasmon resonance, which is much higher than that of SARS-CoV .

ACE2 is a type I transmembrane α-helical protein. It comprises the N-terminal peptidase domain (PD) and C-terminal collectrin-like domain (CLD), involving a small extracellular domain, a long linker as well as a single TM helix. Recently reported that two S protein trimers can simultaneously bind to a human ACE2 homodimer, derived from the cryo-EM data of RBD-ACE2-B 0 AT1 ternary complex, existing as a dimer of heterodimers . Accordingly, mainly the neck domain (residues from 616 to 726) and also the peptidase domain (PD, residues from Ser19 to Asp615) of ACE2 contribute to this stable dimerization (without amino acid transporter B 0 AT1 contribution), through many polar interactions. Existence of the weak interaction at the PD dimer interface reveals its ability to transition to an open conformation, leading to a ~25 Å-separation; thus, the up conformation (open) of RDB in S1 is necessary to bind to ACE2 , which is in line with the results of other recent biophysical studies (Walls et al., 2020; Wrapp et al., 2020) . For recognition, the interaction occurs mainly between an extended loop in the receptor-binding motif (RBM) in the RBD of SARS-CoV-2 S protein (Gln498, Thr500, Asn501, Lys417, Tyr453, Gln474) and the N-terminal α1 J o u r n a l P r e -p r o o f helix of the extracellular PD of ACE2 (Tyr41, Gln42, Lys353, Arg357, Asp30, His34, Gln24) mainly through polar residues that undergo H-bonding (Fig. 4A and 4B ). In line with this result, recently also revealed that the RBD of SARS-CoV-2 comprises the secondary structures of five antiparallel β-sheets, two short α-helices and loops (Lan et al., 2020) . In the RBD of S1 subunit, short β5, β6, α4, α5 and loops constitute the RBM. This RBM is an extended region which includes most of the ACE2-interacting residues. Based on this X-ray crystallographic structure of the SARS-CoV-2 RBD-ACE2 complex, 17 residues in the SARS-CoV-2 RBD have networks with 20 residues of the ACE2 receptor through mainly hydrophilic interactions such as H-bonding and salt bridges. Existence of high structural similarity in the RBD-ACE2 interfaces strongly shows convergent evolutionary relationship between SARS-CoV-2 and SARS-CoV for strong ACE2 binding (Lan et al., 2020) . In agreement with these results, recent studies have reported very similar and complimentary data, including the structural features and hotspots at the RBD-ACE2 interface although usage of different methodologies and sampling procedures . Accordingly, the binding interface between the SARS-CoV-2 RBM and ACE2 forms a larger buried surface, includes a series of hydrophilic residues that makes strong polar contacts, and contains van der Waals contacts and aromatic interactions . It is obviously clear from the biophysical sight that SARS-CoV-2 has important interconnections with ACE2, which will be addressed in the biochemical part through considering its function in Renin-Angiotensin-System. J o u r n a l P r e -p r o o f 

The receptor for SARS-CoV-2, known as ACE2 (angiotensin-converting enzyme 2), is located in host cell surface and it is a membrane-bound homologue of ACE. Additionally, ACE2 has uncovered the interaction between COVID-19 and RAS as it has crucial roles on viral mechanism (Gurwitz, 2020) .

ACE2 is known as a type I membrane protein, and the sites of its expression are mainly the lungs, heart and kidneys. Since the virus uses an enzyme (ACE2) that is part of the RAS, the medications which are commonly used to block the RAS are thought to have a positive effect in the treatment of COVID-19. ACEIs and ARBs are the agents which are related with Renin-Angiotensin System, and they are mainly prescribed for hypertension, congestive heart failure, chronic kidney disease as well as diabetes (Malha et al., 2020) .

Even though ACE and ACE2 share 42% of amino acid identity, they have differences when it comes to enzymatic selectivity and function. These enzymes have significant effects in the Renin-Angiotensin System. Renin enzyme functions in the first step of RAS by catalysing the formation of Ang I (Angiotensin I) from angiotensinogen. The formed Ang I is converted into different molecules that have opposite hemodynamic effects. These molecules are known as vasoconstricting Ang II, and vasodilating Ang (1-7). Ang I is converted into Ang II by ACE, while the formed Ang II is converted into Ang (1-7) by ACE2. Ang II and Ang (1-7) have reverse vascular effects through their distinct receptors.

Ang (1-7) is an antagonist of Ang II-mediated vasoconstriction, and interestingly, its antifibrotic effect was also studied, and thus, Ang (1-7) is thought to protect the lungs from injury due to lung diseases (Malha et al., 2020; Meng et al., 2014) .

The primary route of entry for SARS-CoV-2 happens to be the respiratory system. Even though the kidney contains excessive amounts of ACE2, according to the results of a study, acute kidney injury incidence in COVID-19 was indicated as about 29%, and this incidence can be considered as low when compared to the 71% prevalence of lung injury. Problems regarding to kidneys, which can cause various types of injuries, seen in this disease are thought to be resulting from sepsis, chronic diseases, or an underlying kidney pathology that a patient might have. Other than this, there can be protective effects observed in kidneys that are based on ACE2 (Malha et al., 2020; Yang et al., 2020) .

To enter the cells, SARS-CoV-2 has a specific protein called "Spike" as it binds to ACE2. This event is thought to be the cause of lung injury in COVID-19. Internalization of the virus into the cell causes a reduction in the ACE2, and thus, it is possible to see an increase in Ang II levels. As a result, increased Ang II could cause lung injury by binding to its receptor ATR1 (Gurwitz, 2020; Kuba et al., 2005) . Since COVID-19 became a pandemic, the urgent need for effective therapeutic interventions has led to consider RAS blockage due to its effect on viral entry and lung damage. A hypothesis has derived from the connection between ARBs and ACE2, and it has been stated that ARBs can be beneficial in treating COVID-19 by increasing ACE2 levels (Gurwitz, 2020) . This hypothesis is supported by the consideration of the preventive role of ACE2 in lung damage. The main mechanism behind using ACEIs and ARBs is to prevent the formation of angiotensin 2, and to prevent the angiotensin 2 from functioning by binding its receptor and potentiate lung injury, respectively. Nevertheless, enhancement of the ACE2 may have a different effect on the virus as it can promote viruses to invade the cells (Malha et al., 2020) .

Renin inhibitors and beta-blockers are molecules that can also act on the RAS by decreasing the generation of Ang I, Ang II and Ang (1-7). As it was also stated (Malha et al., 2020) , these agents have J o u r n a l P r e -p r o o f not been focused in the discussion regarding the impact of RAS agents on SARS-CoV-2. Also, it would not be accurate to make conclusive statements on how the alterations on ACE2 in response to ACEIs and ARBs might affect COVID-19, due to limitations in the understanding of the drug action mechanisms on ACE2, and on viral-mediated lung injury (Malha et al., 2020) . Ang II upregulates ACE and downregulates ACE2 expression (Koka et al., 2008) . Therefore, it is expected to see upregulation in ACE2 levels by using ARBs and ACEIs due to their effects on Ang II. However, some studies have shown no increase in ACE2 levels after using ACEIs or ARBs (Burrell et al., 2005; Walters et al., 2017) .

A study was done to understand the effect of Ang II in ACE2 expression in both in vivo and in vitro studies (Deshotels et al., 2014) . According to the study, it has been stated that the absence of Ang II provides the interaction of type I angiotensin receptor (ATR1, the target of ARBs) with ACE2 on the cell membrane. It has been also stated that Ang II reduces the physical interaction between ACE2 and ATR1. On the other hand, Ang II induces ubiquitination and internalization/lysosomal degradation of ACE2 (Deshotels et al., 2014) . Therefore, since ACE2 is the key enzyme used by SARS-CoV-2 for its entry into the cell, the additional results of further studies are needed to understand the main mechanism of the interaction between ACE2 and Ang II, and its effect on viral entry.

Reactive oxygen species (ROS) and reactive nitrogen species (RNS) are produced by several cellular processes in the body (Adams et al., 2015; Finkel, 2011) . These reactive oxygen/nitrogen species (RONS) such as hydroxyl radical (•OH), superoxide anion (O⁻₂), nitric oxide (NO), and peroxynitrite (ONOO⁻) are known as highly reactive molecules due to their unpaired valence electrons (Ntyonga-Pono, 2020). Normally, RONS are important biological molecules having roles in cell signaling and regulation of immune responses (Adams et al., 2015; Schieber and Chandel, 2014) . Under normal physiological conditions, there is a balance between RONS and antioxidants. However, when this balance is disrupted due to the uncontrolled production of oxidants and dysregulation of antioxidant J o u r n a l P r e -p r o o f mechanisms, these powerful oxidants (free radicals) impair cellular functions and cause harmful effects on the body systems (Delgado-Roche and Mesta, 2020). This disruption of the balance between free radicals and antioxidants is called 'oxidative stress' (Yoshikawa and Naito, 2002) .

Additionally, recent studies suggest that oxidative stress has an important role in the severity of SARS-CoV-2 infection, being linked with tissue damage (Laforge et al., 2020) and contributing to the induction of the cytokine storm (Cecchini and Cecchini, 2020).

RAS pathway contributes to the connection between oxidative stress and SARS-CoV-2 infection (Suhail et al., 2020) . Ang II, the important molecule of the RAS pathway, produces reactive oxygen/nitrogen species by stimulating membrane-bound NADPH oxidase (Touyz, 2004; Wen, 2012) .

Additionally, ACE2 is another important molecule that degrades Ang II to Ang 1-7. This degradation results in the lowering of oxidative stress by inhibiting NADPH oxidase, and also preventing the production of RONS induced by Ang II (Lovren et al., 2008) . This information is crucial in understanding the effect of this mechanism on the severity of COVID-19 symptoms. The binding of SARS-CoV-2 Spike protein to ACE2 increases the cellular concentration of Ang II, leading to an increased presence of RONS. This situation results in the occurrence of a cycle of oxidative stress and therefore increases the risk of severe illness from COVID-19 (Suhail et al., 2020) . Additionally, a study has revealed that the reduction of the disulfide bonds of both ACE2 and SARS-CoV-2 Spike protein to thiol groups decreases the affinity of SARS-CoV-2 Spike protein for the ACE2 receptor. However, under oxidative stress, oxidation of thiols to disulfides increases the affinity of SARS-CoV-2 Spike protein for the ACE2 receptor, and therefore, may increase the severity of SARS-CoV-2 infection .

Glutathione is an important tripeptide known for its 'antioxidant effect'. It is involved in several processes such as detoxification, immune response, cellular division, and apoptosis (Forman et al., 2009) . Glutathione exists in two states, reduced (GSH) and oxidized (GSSG). To protect the cells from oxidative stress, GSH reduces ROS and itself turns into its oxidized (GSSG) state (Silvagno et al., 2020) .

It is found that GSH levels and the patient's ability to recover from COVID-19 are connected, and having a high ROS/GSH ratio worsens COVID-19 symptoms (Polonikov, 2020) . Vitamin D is another important molecule known for its antioxidant properties as well as its role in regulating immune function. A low level of vitamin D is also associated with increased severity of COVID-19 symptoms (Razdan et al., 2020) . Therefore, it seems that maintaining an adequate glutathione and vitamin D level is crucial for fighting against COVID-19. There are many factors that can exacerbate or cause severe health issues due to SARS-CoV-2; the following section contains important immunological reactions, which is a response from body to SARS-CoV-2 infection. The molecules that were mentioned in the previous parts can be seen from a different perspective in the following section by understanding their connections and their functions within immunological reactions.

Cytokine Release Syndrome is a significant immunological event considering the SARS-CoV-2 that can affect multiple systems and may even cause death when untreated. It can also be defined as a systemic inflammatory response of human body caused by many factors such as infection and some drugs (Shimabukuro-Vornhagen et al., 2018) . Patients with CRS are at a high risk of infection, and respiratory tract is known as the main site involved in infections. This consideration is derived from the fact that patients are treated with immunosuppressive agents which is a way of lowering their bodies' immune response. Additionally, other facts are defined as immune dysregulation that associated with CRS and having tissue damages mainly at mucosal barriers. In response to damage, tissues release some molecules such as HMGB1 protein, ATP, uric acid, and DNA, which are the part of damage-associated molecular patterns (DAMPs) and function in supporting inflammatory responses. Pathogen recognition receptors (PRRs) are innate immunity receptors, and they can recognize DAMPs. Moreover, PRRs include toll-like receptors (TLRs) and the combining of these two receptors results in the activation of NF-ĸB and the release of cytokines such as IL-1, IL-6, TNFα and also other agents that play role in inflammation (Diamanti et al., 2020) . Cytokine evaluation along J o u r n a l P r e -p r o o f with other molecules carries a significant role regarding COVID-19 patients. To assess the cytokine storm in patients, a study examined immunological features on different patients, including moderate and severe ones. Inflammatory factors were found to be higher in most severe patients.

According to results, TNF-α, IL-6 and IL-10 levels were higher in many of the severe patients. In conclusion, these data may suggest a possible relation between cytokine syndrome and SARS-CoV-2, especially patients with severe symptoms should be evaluated very carefully and treated with these in mind (G. . Furthermore, SARS-CoV-2 induced lung injury may occur in patients, therefore treatment strategies should comprise many aspects of the virus. It was shown that alveolar epithelial cells happen to be the target cells of SARS-CoV-2. Along with ACE2, its main receptor, it can release fibrotic factors, which can induce lung fibrosis. Its mechanism can change gene expression, thus may start lung fibrosis, which can be very dangerous (J. . The diagnostic techniques for these issues will be addressed below.

Clinical features of COVID-19 are known as: dry cough, sore throat, fever, weakness, fatigue, shortness of breath, or difficulty breathing, aches and pains, also including diarrhea, nausea or a runny nose. For those who have mild indications or asymptomatic patients must isolate themselves and consult to a medical provider (Organization, 2020) . Imaging techniques, such as computed tomography (CT), are great opportunities for monitoring the effect of coronavirus on the lungs. By understanding the virus and isolating it, scientists have discovered different ways to detect the viral load. Nonetheless, as mentioned before the RT-PCR test seems to be the gold standard to diagnose the novel coronavirus . The molecular logic of this test depends on taking the nasopharyngeal/oropharyngeal swabs and then the extraction of the viral RNA. With reverse J o u r n a l P r e -p r o o f transcription of the RNA to the complementary DNA, it gets amplificated (Sethuraman et al., 2020) .

There are different genes, of which different regions are targeted by manufacturers, such as virus envelope, virus nucleocapsid, RNA-dependent RNA polymerase gene (RdRp) or ORF1 gene. Cycle threshold, measuring the viral RNA, follows the procedure. It shows how many cycles of replications are needed in order to create a signal. Cycle threshold decreases inversely with increasing RNA loads.

There are even some cases, where the PCR test may remain positive even after 3 weeks of the onset of severe illness, in comparison to mild ones, that are not positive after 3 weeks Sethuraman et al., 2020; Zheng et al., 2020) . Despite the fact that the RT-PCR test is considered as a gold standard diagnostic test, a study estimated the sensitivity to be 0.777 and specificity 0.988 (Padhye and Padhye, 2020) . In comparison to PCR testing, CT scanning has some promising results for detection of the coronavirus and according to a study made in Wuhan, the sensitivity of the CT scans was around 97%, while the sensitivity of RT-PCR was 75% involving approximately a thousand of patients (Ai et al., 2020) .

Besides the conventional methods, nanoparticles also started to acquire an important place when it comes to the detection of the virus. In a comprehensive research, low-cost nanoparticles were synthesized and it was discovered that magnetic nanoparticles could extract viral RNA easily and could be used for 50.000 COVID-19 tests (Chacón-Torres et al., 2020) .

Saliva tests have also become popular with their ability to facilitate taking samples from patients. A study actually used saliva from 25 COVID-19 patients, analysed by RT-PCR, and all of the samples were tested to be positive, which provides a reliable source for the diagnostic criteria (Azzi et al., 2020) . Diagnosis is an important step to come up with effective therapeutic interventions, which can be understood better in the following section.

Currently, there is a global effort and many ongoing researches to find an effective way to treat this viral disease, these efforts include finding a functional vaccine and finding the right therapeutics.

Some of these scientific strategies are now in the development of preclinical and clinical trials. As previously described, one of the most important steps considered as crucial, is the entrance of virus into human cells. There are countless studies searching for the prevention of this viral path. Thus, an urgent development of both effective vaccine alternatives and specific antiviral drugs against SARS-CoV-2 is globally needed. In this regard, broad-spectrum antiviral agents, which were formerly recommended and some of them were used against SARS-CoV and MERS-CoV, are currently considered to be effective against SARS-CoV-2. Hence, the mechanisms of action of these antiviral agents against SARS-CoV-2 are researched continuously.

The only option is the usage of broad-spectrum antiviral drugs such as HIV-protease inhibitors and Nucleoside analogues that could decrease virus infection till specific antiviral agents are found against COVID-19 (Lu, 2020) . At present, nonspecific antiviral and antiflu drugs, including favipiravir, remdesivir (GS-5734), oseltamivir, lopinavir, ritonavir and chloroquine have been clinically used on COVID-19 patients, although there are still some arguments. The broad-spectrum antiviral remdesivir, chloroquine, and hydroxychloroquine were recently shown to be highly effective against COVID-19 (M. Wang et al., 2020) . However, it was also stated that the randomized controlled trials with hydroxychloroquine have not shown an effective result for prolonged survival in COVID-19 (Khuroo, 2020) . As there has been significant debate and controversial data on chloroquine and hydroxychloroquine, a separate section on these drugs has been added (Please see section 6.2).

Favipiravir (a guanosinenucleotid analogue) acts as an inhibitor of RNA-dependent RNA polymerase (RdRp inhibitor) against RNA viruses, and thus, it is considered as a potential agent against SARS-CoV-2, although in vitro and preclinical studies are lacking (Kamps and Hoffmann, 2020; Şimşek Yavuz and Ünal, 2020) . Former studies showed that remdesivir (a nucleotide analog) is another broad antiviral RdRp inhibitor against RNA viruses by increasing the RNA synthesis arrest, including Ebola virus, SARS-CoV and MERS-CoV (Cascella et al., 2020; Gordon et al., 2020; Kamps and Hoffmann, 2020;  J o u r n a l P r e -p r o o f Sheahan et al., 2020 Sheahan et al., , 2017 Şimşek Yavuz and Ünal, 2020; Williamson et al., 2020) , and it was proposed to be an effective compound against coronaviruses (Gordon et al., 2020) . Particularly, the remdesivir treatment in the early stage of COVID-19 was suggested to inhibit the development of pneumonia . In addition, one of the treatments that have been attempted on 75 patients included twice a day orally 75 mg oseltamivir, 500 mg lopinavir (HIV-1 protease inhibitor), 500 mg ritonavir, and intravenously 0.25g ganciclovir for 3-14 days, which are the existing antiviral drugs (N. . Moreover, the antiparasitic drug ivermectin has been researched over and over for a little while. It was shown to have inhibitory effects for nuclear protein import, but also proven that it can be a potential agent for HIV-1 and DENV (Wagstaff et al., 2012) . The process of analyzing the safety of using high-dose ivermectin showed no difference in the intensity of experiencing undesirable results, in comparison to using standard-dose ivermectin (up to 400 μg/kg) (Navarro et al., 2020) . Another study has observed the exposure to ivermectin during pregnancy, and it appears to show no neonatal deaths, preterm labours, or low birth weight but leaves a question, whether ivermectin can cause spontaneous abortions; therefore no proof has been found for the safety of ivermectin during pregnancy (Nicolas et al., 2020) . To test the efficacy of ivermectin against novel coronavirus, one study has focused on in vitro experiments by infecting specific cells with SARS-CoV-2 isolate respectively followed by treatment with ivermectin. In one day, it was seen that ivermectin was able to decrease 93% of viral RNA in the supernatant and 99.8% in cell-associated viral RNA. By two days cells treated with ivermectin were observed even more successfully with a ∼5000-fold reduction of viral RNA resulting in a great reduction in all viral RNA, additionally, no differences were detected at 72 hours. Moreover, at different times there were no toxic effects regarding the ivermectin. Based on these results it was hypothesized that a possible mechanism for ivermectin can be through inhibiting of IMPα/β1-mediated nuclear import of viral proteins (Caly et al., 2020).

J o u r n a l P r e -p r o o f

Hydroxychloroquine (HCQ) and chloroquine (CQ) are the known drugs for some specific diseases, in means of chloroquine has been prescribed for the treatment of malaria and also for preventing infection (chemoprevention), whereas hydroxychloroquine has been used for blood disorders (e.g. porphyria) and also for some autoimmune diseases which are related with joint inflammation (rheumatoid arthritis) and tissue damage (systemic lupus erythematosus) (Saqrane and El Mhammedi, 2020) . In previous studies, HCQ and CQ were used to target SARS-CoV and other coronaviruses (e.g. Feline coronavirus was targeted by both HCQ and CQ, HCoV-229E and HCoV-OC43 were targeted by CQ), and the results of the studies demonstrated the effective in vitro activity of these drugs on targeted coronaviruses (Biot et al., 2006; Keyaerts et al., 2009; Kono et al., 2008) .

As the use of HCQ and CQ was thought to be a potential treatment for COVID-19, these drugs were also used on SARS-CoV-2 infected cells, and this in vitro study resulted in finding HCQ to have higher potency in inhibiting SARS-CoV-2 when compared to CQ . Another study also demonstrated the effects of CQ on SARS-CoV-2, by using Vero E6 cells (M. . The known properties of chloroquine against SARS-CoV infection which are referred as increasing endosomal pH and interfering with the glycosylation of cellular receptor (ACE2), (Vincent et al., 2005) supported the effects of CQ against cell entry stages of SARS-CoV-2, with the EC90 value of 6.90 μM (M. . Additionally, according to the results of more than 100 patients, chloroquine phosphate was found to prevent the worsening of pneumonia and shorten the duration of the disease .

As previously described, the spike protein of coronavirus uses ACE2 receptor for a viral path, thus, new strategies against this protein have become popular to prevent it from cell entry. It has been shown that spike protein also uses sialic acids, which are connected to gangliosides on the cell surface. In other words, SARS-CoV-2 uses different molecules such as sialic acid, gangliosides to ensure its entry to the host cells. Sialic acids in the respiratory tract can be found through J o u r n a l P r e -p r o o f gangliosides or respectively glycoproteins. That is why scientists became interested towards this connection and a possible solution to break it down. According to the study, chloroquine, and hydroxychloroquine (more active form of chloroquine), may be a potential treatment against this novel virus. It was observed that CQ can bind to a specific sialic acid with its cationic group. As well as CQ, HCQ was also able to form a similar connection between sialic acid. Furthermore, it was seen that the OH group of hydroxychloroquine enhanced this binding. Therefore, in the presence of CQ or HCQ, the bond between spike protein and the ganglioside can be prevented, when these drugs bind to the same ganglioside. This may be a new approach of treatment towards patients with COVID-19 (Fantini et al., 2020) .

Although it was formerly proved that these drugs may have antiviral properties, there are still some conflicts around these medications. The mechanism of CQ and HCQ remains different on every individual, especially it can vary between the 3 stages of coronavirus carriers as known as asymptomatic, mild, and severe. Immune system carries a valid role regarding to SARS-CoV-2 but CQ and HCQ can affect immune cells negatively, therefore it can be a major problem when it comes to the treatment of COVID-19 (X. Van Den Borne et al., 1997; Wallace et al., 1994) . In conclusion, the effects, and mechanisms of these drugs on COVID-19 need further investigations both clinically and scientifically.

Since the investigations about the treatment of COVID-19 moves further, the importance of convalescent plasma therapy also raised by considering it as a potential treatment way. This technique is first based on collecting the blood of a person, who has been infected by the virus and then convalesced. The second process is separating the serum which contains increased antibodies in response to antigens. To combat the virus antigen of the newly infected person, the separated serum is injected into the patient. The production source of antibodies is the cells of the immune system which are called as "B cells" , and they can bind to specific molecules on the pathogen which can J o u r n a l P r e -p r o o f activate the immune response and called ''antigen' ' (Ankcorn et al., 2019; .

According to the former studies and reports, it has been confirmed that using convalescent plasma therapy in treating SARS-CoV has positive results, (Cheng et al., 2005; Soo et al., 2004) and these results supported the use of convalescent plasma therapy on SARS-CoV-2 infected patients as well (Shen et al., 2020) .

Recently, convalescent plasma therapy was administrated to 5 patients who were infected severely with SARS-CoV-2, and this administration resulted in an improvement in the clinical status of these patients. However, due to the small number of patients and also the study process, it is thought to be not accurate to make certain statements about this treatment's effectiveness on all COVID-19 patients (Shen et al., 2020) . Researchers also underlined the risks of serum administration, which can be defined as serum sickness (known risk) and antibody-dependent enhancement of infection (theoretical risk). The known risk, serum sickness, is related to the transmission of infectious agents and triggering immunological reactions. However, antibody-dependent enhancement of infection is not considered as a known concern, and it is related to the enhancement of the infection to a different viral strain by antibodies to one form of coronavirus (Casadevall and Pirofski, 2020). Therefore, this concern raises the importance of determining the human monoclonal antibody for its role of neutralizing SARS-CoV-2.

In the section of "Structural and functional features of SARS-CoV-2" (above), it has been described in detail that the RBD of the S protein is the most variable part in SARS-CoV-2 with having crucial amino acids for binding to ACE2 receptor (Andersen et al., 2020; Wu et al., 2020; Zhou et al., 2020) . This spike protein contains two significant subunits known as S1 and S2 subunits. The known role of S1 subunit is receptor binding, whereas S2 subunit is responsible for membrane-fusion. Thus, the epitopes of the spike protein are considered as specific targets for design of vaccine, neutralizing antibodies, or drug agents. A study was conducted on the effect of the anti-S1 human monoclonal antibody 80R on SARS-CoV, and it resulted in the antibody binding to the conformational epitope on J o u r n a l P r e -p r o o f the S1 fragment and neutralizing SARS-CoV. The interaction between S1 subunit and ACE2 can also be prevented by this way (Sui et al., 2004) . It is known that SARS-CoV-2 and SARS-CoV have different receptor binding domains (RBDs). According to another study, it has been shown that m396 and CR3014, which are the specific neutralizing antibodies for SARS-CoV spike protein, do not have ability to bind the spike protein of SARS-CoV-2. However, it was reported that at a concentration of 23.5μg/ml, the antibody CR3022 can neutralize both SARS-CoV and SARS-CoV-2. Therefore, usage of CR3022 alone or by combining it with other neutralizing antibodies as potential therapeutics against COVID-19 was suggested .

By discovering the virus in a more detailed aspect, scientists have come through a lot of new treatment methods as mentioned before. Besides antiviral agents and plasma therapy, there are various methods that are being tried currently as well. Corticosteroid therapy has been newly searched. According to a study made with dexamethasone, it was found that it can be a potential method against acute respiratory distress syndrome (ARDS). It was revealed that moderate to severe ARDS patients receiving dexamethasone had more ventilator-free days than the control group (Villar et al., 2020) . Another prospective study called the recovery trial in the UK found out 35% of reduction in the mortality rate, when the patients with mechanical ventilation received 6 mg of dexamethasone for 10 days. With that being said, there wasn't such benefit on mild to moderate cases .

Another study made in the USA searched for the effects of prophylactic anticoagulation against SARS-CoV-2 related deaths. It is known that this novel coronavirus can cause venous thromboembolism, which can lead to death (Bikdeli et al., 2020) . The cohort study in the USA investigated the effects of prophylactic anticoagulation on patients admitted to the hospital with SARS-CoV-2, and they found that patients, who receive anticoagulation, had less risk of mortality.

Furthermore, they also found that prophylactic anticoagulation had no association with severe bleeding (Rentsch et al., 2021) .

Cenicriviroc is also another agent which is newly being searched for. It is a chemokine receptor antagonist additionally having anti-viral and anti-inflammatory characteristics. In an in vitro research, they found that cenicriviroc happened to have inhibitory properties against SARS-CoV-2 (Okamoto et al., 2020). An additional study dwelled on the agonist of the stimulator of interferon genes (STING) and its potential inhibitory mechanism against SARS-CoV-2. STING has many features including the control of host defence mechanism and immune pathway (Barber, 2015) . It was shown that an agonist of STING, dimeric amidobenzimidazole (diABZI) was efficient against SARS-CoV-2 but also common cold coronavirus known as HCoV-229E. They discovered that even in low dose of diABZI treatment, it was possible to prevent epithelial damage of the respiratory system (Zhu et al., 2021) .

To stop the COVID-19 globally, effective vaccine alternatives are required as protective measures.

Thus, it is obvious that clarifying the structural and functional properties of SARS-CoV-2 with biophysical and biochemical methods is an important fundamental study, and such studies can be transformed into practice. Since the beginning of the pandemic, scientists and research institutes have come a long way and made inroads into treatment strategies. With that being said, there are currently various types of vaccines available for the COVID-19 by using special types of techniques and efficacies. There are various factors which should be considered about vaccination and its prospects.

A study was performed to find out the percentage of vaccine protection that can be efficient to prevent an epidemic. It was revealed that at least 70% of protection by vaccination of 75% of the population is required to prevent an epidemic, and, with further confirmation, they found that in order to annihilate an ongoing epidemic the efficacy level of the vaccine should increase up to 80%. It can be seen that going back to normal life would require much efficacy and high coverage of the population. Nevertheless, these data do not mean that vaccines will be inadequate if they are less effective. The same study found that even in the case of 40% of protection, millions of people can be J o u r n a l P r e -p r o o f saved from ventilator and hospital bed days can be reduced. In short terms, a vaccination can save millions of lives (Bartsch et al., 2020) . Besides the protection level, vaccines also vary according to their types such as mRNA vaccines, adenovirus vaccines or conventional inactivated vaccines.

Funded by BioNTech and Pfizer; BNT162b2 mRNA vaccine was one of the first ones released for usage. The logic for mRNA vaccine comes from injecting synthetic mRNA, which encodes viral antigens and thus causes an immune response. It stimulates the human cells to produce spike protein, to which, in return, the human body develops antibodies. Once the protein is produced, mRNA is removed by the cell. In comparison to conventional methods, they can be improved and produced very rapidly (Cao and Gao, 2021; Pardi et al., 2018) . Clinical trials for BNT162b2 vaccine included more than forty thousand people, who received 2 doses of vaccine or placebo with 3 weeks of break. According to participants, local reactions were mostly due to pain, lower percentage of some participants also reported swelling or redness at the injection region. Overall, the complications were mild to moderate. Moreover, the percentage of severe systemic reactions was less than 0.9%, and most of the participants complained about a mild headache and fatigue. The efficacy of vaccine turned out to be quite decent with being almost 95%. However, the trial left some remained questions by not including pregnant women, immunocompromised patients, and children (Polack et al., 2020) .

Besides mRNA vaccines, there are adenovirus vaccines such as ChAdOx1 nCoV-19 vaccine, known as AZD1222, which was developed at the Oxford University. It has an adenoviral vector that includes the spike protein. The study, which comprised different continents with 4 trials, found that ChAdOx1 nCoV-19 has around 70% protection without any severe cases of health concerns (Voysey et al., 2021) . Another adenovirus vaccine was developed in the United States named Johnson and Johnson;

it was further revealed that J&J vaccine was able to prevent moderate to severe cases at 66% with one additional shot (Livingston et al., 2021) . J o u r n a l P r e -p r o o f

Clinical and immunological features of severe and moderate coronavirus disease 2019

Convalescent plasma as a potential therapy for COVID-19

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

Use of convalescent plasma therapy in SARS patients in Hong Kong

Molecular Diagnosis of a Novel Coronavirus (2019-nCoV) Causing an Outbreak of Pneumonia

Origin and evolution of pathogenic coronaviruses

Oxidative Stress as Key Player in Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) Infection

Angiotensin II mediates angiotensin converting enzyme type 2 internalization and degradation through an Angiotensin II type I receptor-dependent mechanism

Cytokine release syndrome in COVID-19 patients, a new scenario for an old concern: The fragile balance between infections and autoimmunity

Covid-19: Chinese vaccines may need changes to improve efficacy, admits official

COVID-19 and SARS-CoV-2. Modeling the present, looking at the future

Structural and molecular modelling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infection

Biochemical and biophysical characterization of the main protease, 3-chymotrypsin-like protease (3CLpro) from the novel coronavirus SARS-CoV 2

Signal transduction by reactive oxygen species

Glutathione: Overview of its protective roles, measurement, and biosynthesis

Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies

The antiviral compound remdesivir potently inhibits RNAdependent RNA polymerase from Middle East respiratory syndrome coronavirus

Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics

Impact of Thiol-Disulfide Balance on the Binding of Covid-19 Spike Protein with Angiotensin-Converting Enzyme 2 Receptor

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Structure-based design of prefusion-stabilized SARS-CoV-2 spikes

Characteristics of SARS-CoV-2 and COVID-19

Is hydroxychloroquine beneficial for COVID-19 patients?

Positive rate of RT-PCR detection of SARS-CoV-2 infection in 4880 cases from one hospital in

The Johnson & Johnson Vaccine for COVID-19

Angiotensin converting enzyme-2 confers endothelial protection and attenuates atherosclerosis

Drug treatment options for the 2019-new coronavirus (2019-nCoV)

Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding

Molecular epidemiology, evolution and phylogeny of SARS coronavirus

COVID-19 and the Renin-Angiotensin System

Interaction of severe acute respiratory syndrome-coronavirus and NL63 coronavirus spike proteins with angiotensin converting enzyme-2

Angiotensinconverting enzyme 2/angiotensin-(1-7)/mas axis protects against lung fibrosis by inhibiting the MAPK/NF-κB pathway

Insights into SARS-CoV-2 genome, structure, evolution, pathogenesis and therapies: Structural genomics approach

Safety of high-dose ivermectin: A systematic review and meta-analysis

Safety of oral ivermectin during pregnancy: a systematic review and meta-analysis

COVID-19 infection and oxidative stress: an under-explored approach for prevention and treatment?

SARS-CoV-2 and the COVID-19 disease: A mini review on diagnostic methods

Coronavirus (Symptoms)

Summary of probable SARS cases with onset of illness from 1

Reconstructed diagnostic sensitivity and specificity of the RT-PCR test for COVID-19

mRNA vaccines-a new era in vaccinology

Coronaviridae, in: Fields Virology

Coronaviruses, in: Medical Microbiology: Eighteenth Edition

Coronaviruses post-SARS: Update on replication and pathogenesis

Manifestations and Death in COVID-19 Patients

Vitamin D Levels and COVID-19 Susceptibility: Is there any Correlation?

Identification of a novel coronavirus causing severe pneumonia in human: a descriptive study

Early initiation of prophylactic anticoagulation for prevention of coronavirus disease 2019 mortality in patients admitted to hospital in the United States: Cohort study

The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak

Review on the global epidemiological situation and the efficacy of chloroquine and hydroxychloroquine for the treatment of COVID-19

ROS function in redox signaling and oxidative stress

Coronavirus envelope protein: Current knowledge

Interpreting Diagnostic Tests for SARS-CoV-2

Structural basis of receptor recognition by SARS-CoV-2

Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV

Treatment of 5 Critically Ill Patients with COVID-19 with Convalescent Plasma

Cytokine release syndrome

The role of glutathione in protecting against the severe inflammatory response triggered by covid-19

Antiviral treatment of covid-19

Role of corticosteroid in the management of COVID-19: A systemic review and a Clinician's perspective

Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients

Role of Oxidative Stress on SARS-CoV (SARS) and SARS-CoV-2 (COVID-19) Infection: A Review

Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association

Introduction of the South African SARS-CoV-2 variant 501Y.V2 into the UK

Coronavirus membrane fusion mechanism offers a potential target for antiviral development

Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa

Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody

Timeline of WHO's response to COVID-19

Unexpected free fatty acid binding pocket in the cryo-EM structure of SARS-CoV-2 spike protein

Reactive oxygen species and angiotensin II signaling in vascular cells -Implications in cardiovascular disease

Chloroquine and hydroxychloroquine equally affect tumor necrosis factor-α, interleukin 6, and interferon-γ production by peripheral blood mononuclear cells

Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre

Chloroquine is a potent inhibitor of SARS coronavirus infection and spread

SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil

Angiotensin converting enzyme 2 activity and human atrial fibrillation: Increased plasma angiotensin converting enzyme 2 activity is associated with atrial fibrillation and more advanced left atrial structural remodelling

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2

Site-specific glycan analysis of the SARS-CoV-2 spike. Science (80-. )

Oxidative stress-mediated effects of angiotensin II in the cardiovascular system

Coronavirus disease (COVID-19) advice for the public. Coronavirus Dis

WHO | SARS-CoV-2 Variants

WHO Director-General's remarks at the media briefing on

Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2

Covid-19: New coronavirus variant is identified in UK

International travel and health SARS (Severe Acute Respiratory Syndrome)

WHO | World Health Organization issues emergency travel advisory

SARS: breaking the chains of transmission

World Health Organization (WHO), 2020a. Novel Coronavirus ( 2019-nCoV ) Situation Report -1

World Health Organization (WHO), 2020b. Coronavirus disease 2019 (COVID-19) Situation Report -51

Cryo-EM Structure of the 2019-nCoV Spike in the Prefusion Conformation. Science

A new coronavirus associated with human respiratory disease in China

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, doubleblind, placebo-controlled, phase 1/2 clinical trial

Yang, Xiaoming, 2021. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind

SARS-CoV-2 induces transcriptional signatures in human lung epithelial cells that promote lung fibrosis

Imaging and clinical features of patients with 2019 novel coronavirus SARS-CoV-2

Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study

In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

Architecture and self-assembly of the SARS

The Proteins of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS CoV-2 or n-COV19), the Cause of COVID-19

Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province

A pneumonia outbreak associated with a new coronavirus of probable bat origin

A novel coronavirus from patients with pneumonia in China

Inhibition of coronavirus infection by a synthetic STING agonist in primary human airway system